Teva Pharmaceutical Industries Limited (TEVA)

NYSE: TEVA · Real-Time Price · USD

15.48

-0.10 (-0.64%)

At close: Apr 30, 2025, 2:09 PM

Teva Pharmaceutical Industries Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Revenue	16.54B	15.85B	14.93B	15.88B	16.66B	16.89B	18.85B	22.39B	21.9B
Cost of Revenue	8.48B	8.2B	7.95B	8.28B	8.93B	9.35B	10.56B	11.56B	10.04B
Gross Profit	8.06B	7.65B	6.97B	7.59B	7.72B	7.54B	8.3B	10.82B	11.86B
Operating Income	-303M	433M	2.8B	3.2B	3.05B	2.8B	-1.64B	-17.48B	2.15B
Interest Income	-48M	68M	920M	891M	24M	41M	n/a	3M	n/a
Pretax Income	-1.28B	-624M	-3.06B	658M	-4.41B	-1.26B	-2.6B	-18.38B	824M
Net Income	-1.64B	-559M	-2.35B	417M	-3.99B	-999M	-2.15B	-16.27B	329M
Selling & General & Admin	3.7B	3.5B	3.44B	3.53B	3.67B	3.81B	4.21B	4.99B	5.1B
Research & Development	998M	953M	838M	967M	997M	1.01B	1.21B	1.85B	2.11B
Other Expenses	3.67B	2.76B	107M	98M	-4M	76M	291M	1.2B	636M
Operating Expenses	8.37B	7.21B	4.28B	4.5B	4.67B	4.82B	5.43B	6.83B	7.21B
Interest Expense	1B	1.03B	966M	1.06B	963M	822M	881M	895M	1.33B
Selling & Marketing Expenses	2.54B	2.34B	2.27B	2.43B	2.5B	2.61B	2.92B	3.66B	3.86B
Cost & Expenses	16.85B	15.41B	12.23B	12.78B	13.6B	14.17B	15.98B	18.39B	17.25B
Income Tax Expense	355M	-7M	-638M	211M	-168M	-278M	-195M	-1.93B	521M
Shares Outstanding (Basic)	1.13B	1.12B	1.11B	1.1B	1.09B	1.09B	1.02B	1.02B	955M
Shares Outstanding (Diluted)	1.13B	1.12B	1.11B	1.11B	1.09B	1.09B	1.02B	1.02B	961M
EPS (Basic)	-1.45	-0.5	-2.12	0.38	-3.64	-0.92	-2.11	-16.01	0.07
EPS (Diluted)	-1.45	-0.5	-2.12	0.38	-3.64	-0.92	-2.11	-16.01	0.07
EBITDA	-303M	1.57B	-874M	4.41B	-2.09B	1.28B	186M	-15.52B	2.87B
EBIT	-282M	405M	-2.23B	1.55B	-3.65B	-443M	-1.66B	-17.59B	1.37B
Depreciation & Amortization	-21M	1.15B	1.31B	1.33B	1.56B	1.72B	1.84B	2.08B	1.49B